A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Lidocaine (Primary)
- Indications Interstitial cystitis; Pain
- Focus Therapeutic Use
- Sponsors Allergan; TARIS Biomedical
- 19 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 24 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 09 Apr 2013 New source identified and integrated: ClinicalTrials.gov record.